ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

NCI Expects Centers To Increase Cancer Control Efforts Despite Various Obstacles They Face

January 16, 1987

ASCO Supports CT Scans For Colorectal Screening

November 25, 2005

Pitt Seeks Biostatistician For NSABP, Hearing Delayed a Week

September 23, 1994

Women’s Health Initiative Trial Produced $37.1 Billion in Returns

May 9, 2014

NCI advisory panel recommends funding a 10-year Human Cancer Genome Project with $1.35 billion in new money.

March 18, 2005

FDA Approves Generic Oncology Injectable Currently In Shortage

September 27, 2013